Market Overview

Credit Suisse: We Prefer Pfizer, Bristol Over Pharma Peers

Share:
Credit Suisse: We Prefer Pfizer, Bristol Over Pharma Peers

Credit Suisse reviewed its stances on major U.S. pharma names in a note this week, though the analysts came to the same conclusion that Bristol-Myers Squibb Co (NYSE: BMY) and Pfizer Inc (NYSE: PFE) were the best in class. The analysts also noted that they have an Outperform rating on AbbVie Inc (NYSE: ABBV).

Alongside this analysis, Credit Suisse increased its price targets for Bristol-Myers, from $70 to $75, Pfizer, from $36 to $37, while leaving its AbbVie price target unchanged at $69. The analysts also increased their price targets for Eli Lilly and Co (NYSE: LLY) by $1 to $72 and Merck & Co., Inc. (NYSE: MRK) by $2 to $62. Credit Suisse rated both of those stocks at Neutral.

For Bristol-Myers, the analysts pointed to the early stop of its CheckMate ‘057 Opdivo trial study as reason to increase its near-term immuno-oncology estimates. Based on a discounted cash flow analysis, Credit Suisse forecasted operating margins of 45 percent in 2023, driven by a 1.5 percent "terminal growth rate."

Likewise, the early stop of Pfizer's PALOMA-3 trial from positive results has Credit Suisse increasing both the near- and long-term estimates of Ibrance. The analysts said that its estimates and outlook does not include Pfizer's acquisition of Hospira, Inc. (NYSE: HSP).

Arguably, Credit Suisse is least optimistic on Johnson & Johnson (NYSE: JNJ), revising its price target lower to $108, from $110 prior. That price target does still reflect 8 percent upside in the stock, however.

Latest Ratings for BMY

DateFirmActionFromTo
Jan 2020CitigroupReinstatesBuy
Dec 2019Argus ResearchUpgradesHoldBuy
Nov 2019Gabelli & Co.Initiates Coverage OnBuy

View More Analyst Ratings for BMY
View the Latest Analyst Ratings

Posted-In: bristol-myers squibb Credit Suisse PfizerAnalyst Color Biotech Price Target Analyst Ratings General Best of Benzinga

 

Related Articles (BMY + ABBV)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
ARDSRoth CapitalInitiates Coverage On18.0
PTCBairdAssumes
MNPRBrookline CapitalInitiates Coverage On42.0
HCKTCraig-HallumUpgrades
HNPDaiwa CapitalDowngrades
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com